Clinical trials: Psilocybin, open to volunteers
Treatment-resistant Depression (TRD)
Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression
Psilocybin-assisted psychotherapy requires a lot of resources, with more psychotherapy being provided to integrate the meanings and insights derived from the psilocybin dosing sessions.
- Trial name
- PSI-GROUP (NCT07737990)
- Testing
- Group integration therapy
- Where
- Canada
- Volunteers
- 65 people
- Sponsor
- Joshua Rosenblat
PTSD
Psilocybin-Assisted Therapy
This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms.
- Trial name
- NCT07332143
- Testing
- psilocybin, Supportive Therapy, Prolonged Exposure Therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Emory University
Opioid Use Disorder
Wellcome Leap Psilocybin for OUD
Investigators will recruit 36 individuals on MAT for OUD for a double-blind, placebo-controlled design to determine whether PEX010 (25-mg/d) shows preliminary efficacy on neural correlates of neurocognition and on clinical…
- Trial name
- NCT06786325
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Anna Rose Childress, Ph.D.
Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI
Psilocybin Microdosing on Cognition, Mood and Quality of Life
This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/functional MRI results compared to a placebo.
- Trial name
- NCT07449351
- Testing
- Psliocybin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Yale University
Major Depression
Study of Psilocybin Under Anesthesia Controlled by EEG
Major depressive disorder (MDD) affects millions of Americans and remains difficult to treat. Psilocybin, a psychedelic compound, has shown promise for reducing depression symptoms, but a key challenge in psychedelic research is…
- Trial name
- SPACE (NCT07479550)
- Testing
- Psilocybin (Usona Institute), Propofol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Stanford University
Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD
The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training
The study investigates two groups of participants of the SÄPT therapist's training starting in October 2022. The overall objective is to investigate the risks and benefits of personal experience (PE) with substance-induced…
- Trial name
- TherPsySE (NCT05570708)
- Testing
- MDMA, LSD, psilocybin
- Where
- Switzerland
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Felix Mueller
Treatment Resistant Depression
Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression
Objective: To assess the safety and efficacy of a six-week microdosing regimen of psilocybin combined with short-term, experience-based psychotherapy in patients with treatment-resistant depression who have not responded to…
- Trial name
- NCT07183748
- Testing
- Psilocybin (drug)
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Beersheva Mental Health Center
Healthy, Psychedelic Experiences
The ENHANCE Study: taVNS and Psilocybin
This study will examine whether combining a single dose of psilocybin with non-invasive transcutaneous auricular vagus nerve stimulation (taVNS), a potential inducer of neuroplasticity and enhanced memory formation, will enhance…
- Conditions
- Healthy, Psychedelic Experiences, Vagus Nerve Stimulation
- Trial name
- ENHANCE (NCT05866471)
- Testing
- Psilocybin, Transcutaneous auricular Vagus Nerve Stimulation (taVNS), Psychosocial Support Alone
- Where
- United States
- Volunteers
- 115 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Borderline Personality Disorder, Borderline Personality Pathology
ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder
ADEPT is an open-label proof-of-concept study evaluating the safety and tolerability of psilocybin-assisted therapy in conjunction with Dialectical Behavior Therapy for participants with borderline personality disorder.
- Conditions
- Borderline Personality Disorder, Borderline Personality Pathology, Depressive Symptoms, Emotion Dysregulation
- Trial name
- ADEPT (NCT07833761)
- Testing
- Psilocybin, Psilocybin-Assisted Therapy With Dialectical Behavior Therapy
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- University of Minnesota
Depression, Anxiety, Psilocybin-Assisted Psychotherapy
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
To learn about the feasibility, safety, and effects of psilocybin-assisted psychotherapy on depression and/or anxiety in participants who are being treated for advanced cancer.
- Conditions
- Depression, Anxiety, Psilocybin-Assisted Psychotherapy, Advanced Cancer
- Trial name
- NCT06200155
- Testing
- Psilocybin, Niacin
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Treatment Resistant Depression, Substance Use Disorders
Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder
The goal of this clinical trial is to learn if a single dose of psilocybin (5mg Vs 10mg Vs 25mg) alongside psychotherapy is safe and can help treat treatment resistant depression (TRD) with co-occurring substance use disorder…
- Trial name
- NCT07499583
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Indiana University
Healthy Volunteer, Older Adults (65-85 Years)
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults
This study plans to learn more about the safety and tolerability of psychedelic administration (psilocybin) in healthy older adults ages 65-85.
- Trial name
- Psil-Pk (NCT07516405)
- Testing
- Psilocybin (Usona Institute)
- Where
- 6 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Breast Cancer, Ovarian Cancer
Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence
The goal of this clinical trial is to test whether psilocybin along with therapy in women with early breast cancer and ovarian cancer in remission can improve their fear of recurrence.
- Trial name
- NCT06430541
- Testing
- Psilocybin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- University of Colorado, Denver
Treatment-Resistant Major Depressive Disorder
Understanding Music and Mindfulness Preferences in Psilocybin-Assisted Psychotherapy
The goal of this pilot clinical trial is to learn whether it is feasible to individually tailor psilocybin-assisted psychotherapy (PAP) for people with treatment-resistant depression (TRD) based on their personal preferences.
- Trial name
- PPP (NCT07373535)
- Testing
- Psilocybin 25mg, Music-centered psilocybin-assisted therapy, Mindfulness-centered psilocybin-assisted therapy
- Where
- 2 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Kyle Greenway
Posttraumatic Stress Disorder
Psilocybin and Methylenedioxymethamphetamine (MDMA) for Post-traumatic Stress Disorder (PTSD)
The purpose of this study is to assess the safety and effectiveness of co-administered MDMA and psilocybin in military Veterans with a diagnosis of Posttraumatic Stress Disorder (PTSD).
- Trial name
- PAM-VET (NCT06989957)
- Testing
- Psilocybin, MDMA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Investigating the Importance of the Subjective Psychedelic Experience
Subjective Experience Following Psilocybin
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes.
- Trial name
- SEP-1 (NCT06768944)
- Testing
- Psilocybin high-dose, Psilocybin low-dose, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Major Depressive Disorder
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
This is an interventional, parallel arm assignment treatment study in individuals with Major Depressive Disorder (MDD). Each individual will be treated with a single dose of pimavanserin or placebo plus a single dose of…
- Trial name
- NCT06592833
- Testing
- Psilocybin, Pimavanserin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD)
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
The goal of this clinical trial is to determine the safety and efficacy of psilocybin assisted Therapy (PAT) in individuals with comorbid Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
- Trial name
- NCT07405606
- Testing
- Psilocybin 25 mg
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Centre for Addiction and Mental Health
Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD)
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ)
Psilocybin, a serotonin receptor agonist in the brain, significantly and quickly improves depressive symptoms while inducing profound acute subjective effects.
- Trial name
- PSILOTRAZ (NCT07210112)
- Testing
- Psilocybin 25 mg per os, Trazodone 5mg, Trazodone 30 mg
- Where
- France
- Volunteers
- 112 people
- Sponsor
- Centre Hospitalier St Anne
Spinal Cord Injury, Depression - Major Depressive Disorder
Psilocybin to Treat Depression in Spinal Cord Injury
The main goal of this study is to determine if psilocybin is safe for use in people with SCI. The study will measure how people with SCI respond to three psilocybin doses: low (5mg), medium (10mg), and high (25mg).
- Conditions
- Spinal Cord Injury, Depression - Major Depressive Disorder, Veteran
- Trial name
- STOP (NCT07251491)
- Testing
- Psilocybin (Usona Institute)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- James J. Peters Veterans Affairs Medical Center